A three-year-old child with metastatic hepatoblastoma, a rare type of liver cancer that mainly affects young children, has achieved complete remission after receiving two doses of CAR-T therapy. The disease had already spread to the lungs and bones before treatment, but 12 months after the therapy, no detectable cancer cells were found, aside from a residual scar. These results suggest that this treatment approach could be explored for other solid tumors, which are typically more difficult to treat than blood cancers. Hepatoblastoma is a rare but aggressive form of liver cancer, often diagnosed in children under five. It may present with symptoms such as an abdominal mass, weight loss, weakness, or fatigue. Although advances in early diagnosis and treatment have improved survival rates to nearly 80 percent, some patients still develop resistance to existing therapies, highlighting the need for new and more effective strategies. CAR-T cell therapy, a type of immunotherapy, involves modifying a patient’s immune cells to target and destroy cancer cells. While it has shown success in treating certain blood cancers, it has faced challenges in treating solid tumors like hepatoblastoma due to the complex structure of these tumors and the presence of proteins in healthy tissues that can interfere with the therapy. A team of doctors, co-led by Baylor College of Medicine and Texas Children’s Hospital, reported that a child with metastatic hepatoblastoma achieved complete remission after two doses of CAR-T therapy. The treatment specifically targeted glypican-3, a protein found in liver tumors but not in healthy adult tissues. The therapy also included genes that produce interleukin-15 and interleukin-21, which help enhance the ability of the CAR-T cells to persist and fight the cancer. At diagnosis, the boy had a large tumor in the left lobe of his liver, which had spread to his lungs and bones. He underwent chemotherapy, surgery to remove the primary tumor, and additional surgeries to remove cancer from his lungs. Despite these interventions, the cancer continued to spread, prompting the use of CAR-T therapy. After receiving two doses of GPC3-CAR therapy at eight-week intervals, the boy showed a partial response after the first infusion, with a decrease in alpha-fetoprotein levels, a marker for liver cancer. Following the second infusion, no signs of the disease were detected except for a scar. Twelve months later, he remained in complete remission. Researchers believe the success may be due to the relatively low tumor burden and the location of the relapse in the lungs, which may have made the therapy more effective. Trials are continuing on other patients within the CARE study, offering hope for future treatments for similar cancers.